Literature DB >> 16642542

Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment.

Luca Rozzini1, Barbara Vicini Chilovi, Erik Bertoletti, Marta Conti, Ilenia Del Rio, Marco Trabucchi, Alessandro Padovani.   

Abstract

BACKGROUND: Predictors of progression to dementia in individuals with mild cognitive impairment (MCI) define different groups with higher risks of progression. To date, efforts to differentiate those who will progress to dementia from those who will not have proved inconclusive, and while grades of risk have been identified, their generalizability is not clear. AIM: To examine the clinical and socio-demographical risk factors for progression of memory decline in a sample of subjects with referred memory complaints who met criteria for amnestic MCI. METHODS AND MATERIALS: Seventy-four subjects consecutively recruited who met the operational criteria for amnestic MCI. They underwent multidimensional assessment and a neuropsychological battery at baseline and at follow-up, after one year. Memory decline was defined using the short story mean score change (at follow-up and at baseline). Subjects showing memory decline, with or without conversion to AD over time, were classified as having progressive MCI; subjects that remained unchanged or improved during follow-up were considered as having stable MCI.
RESULTS: Subjects with progressive MCI (n = 39, 53%) were older (p = <0.001) and more educated (p = 0.01) compared to stable MCI (n = 35, 47%) and their global cognitive performances, at baseline, were more compromised when assessed by ADAS-Cog (p = 0.05). Antihypertensive drug prescription was greater in the stable MCI compared to progressive MCI (p = 0.01) and significant higher levels of plasma total homocysteine were observed in progressive MCI (p = 0.03). When analyzed in a logistic regression model, the prescription of Angiotensin Converting Enzyme Inhibitors (ACE) was found to be independently associated to the stability of cognitive function, whereas older age, higher education, higher levels of plasma total homocysteine and total ADAS-Cog basal score were independently associated with the progression of cognitive decline.
CONCLUSIONS: Older age, higher education, poor global cognitive performance, higher levels of plasma total homocysteine are independently associated with the progression of memory decline while the prescription of ACE Inhibitors is a protective factor for cognitive deterioration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16642542     DOI: 10.1002/gps.1523

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  27 in total

1.  No association of angiotensin I converting enzyme I/D polymorphism with domain-specific cognitive function in aged men without dementia.

Authors:  Mu-En Liu; Shih-Jen Tsai; Ti Lu; Cheng-Jee Hong; Ming-Chao Chen; Shoa-Lin Lin; Heng-Liang Yeh; Yan-Chiou Ku
Journal:  Neuromolecular Med       Date:  2011-08-11       Impact factor: 3.843

2.  The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial.

Authors:  Whitney Wharton; James H Stein; Claudia Korcarz; Jane Sachs; Sandra R Olson; Henrik Zetterberg; Maritza Dowling; Shuyun Ye; Carey E Gleason; Gail Underbakke; Laura E Jacobson; Sterling C Johnson; Mark A Sager; Sanjay Asthana; Cynthia M Carlsson
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse.

Authors:  Linda Ferrington; Laura E Palmer; Seth Love; Karen J Horsburgh; Paul At Kelly; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2012-04-12       Impact factor: 4.060

4.  Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Linda Ferrington; J Scott Miners; Laura E Palmer; Susan M Bond; Joanne E Povey; Paul At Kelly; Seth Love; Karen J Horsburgh; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2011-02-05       Impact factor: 4.060

Review 5.  [Diagnosis without therapy: early diagnosis of Alzheimer's disease in the stage of mild cognitive impairment].

Authors:  H-J Gertz; A Kurz
Journal:  Nervenarzt       Date:  2011-09       Impact factor: 1.214

6.  The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration.

Authors:  J Ellul; N Archer; C M L Foy; M Poppe; H Boothby; H Nicholas; R G Brown; S Lovestone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-29       Impact factor: 10.154

7.  Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging.

Authors:  Vincenzo Solfrizzi; Emanuele Scafato; Vincenza Frisardi; Davide Seripa; Giancarlo Logroscino; Patrick G Kehoe; Bruno P Imbimbo; Marzia Baldereschi; Gaetano Crepaldi; Antonio Di Carlo; Lucia Galluzzo; Claudia Gandin; Domenico Inzitari; Stefania Maggi; Alberto Pilotto; Francesco Panza
Journal:  Age (Dordr)       Date:  2011-12-28

8.  ACE variants and association with brain Aβ levels in Alzheimer's disease.

Authors:  J Scott Miners; Zoë van Helmond; Merryn Raiker; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2010-10-15       Impact factor: 4.060

9.  Latest Advances on Interventions that May Prevent, Delay or Ameliorate Dementia.

Authors:  Danielle Wilson; Ruth Peters; Karen Ritchie; Craig W Ritchie
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

10.  Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.

Authors:  Nien-Chen Li; Austin Lee; Rachel A Whitmer; Miia Kivipelto; Elizabeth Lawler; Lewis E Kazis; Benjamin Wolozin
Journal:  BMJ       Date:  2010-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.